** Drug developer Allakos' ALLK.O shares fall 72.7% to 33 cents premarket
** Co says its experimental drug, AK006, did not show clinical benefit in an early-stage trial testing it in patients with chronic spontaneous urticaria — a skin condition that causes itching and hives
** As a result, the company has decided to discontinue further clinical development of AK006
** Co also plans to reduce its workforce by 75%
** Co plans to retain about 15 employees to explore strategic alternatives, maintain compliance with regulatory and financial reporting requirements, and wind-down the early-stage trial
** Estimates it will have cash, cash equivalents and investments in a range of approximately $35 mln to $40 mln at June 30, 2025
** Stock had fallen 55.7% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。